NeuroPace (NPCE) Other Non-Current Liabilities (2020 - 2021)
NeuroPace's quarterly Other Non-Current Liabilities came in at $248000.0 in Q3 2021, down 9.49% quarter-over-quarter from $274000.0 in Q1 2021.
NeuroPace has reported Other Non-Current Liabilities for 2 years, with the latest figure at $248000.0 in Q3 2021.
- For the quarter ending Q3 2021, Other Non-Current Liabilities changed N/A year-over-year to $248000.0; the trailing twelve-month figure through Sep 2021 stood at $248000.0 (changed N/A YoY), and the FY2020 full-year result was $274000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q3 2021 stood at $248000.0, down from $274000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $274000.0 in Q4 2020, with the low at $248000.0 in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NeuroPace | 558.86 Mn | 504.88 Mn | 18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 248,000.00 |
| Mar 31, 2021 | 274,000.00 |
| Dec 31, 2020 | 274,000.00 |